Strides Pharma Science Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg".
Press Release Apr 30 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Strides Pharma Science Ltd on 6ix
Earlier from Strides Pharma Science
- Press Release Jan 30 2025
- Intimation of Board Meeting scheduled on January 30, 2025
- Press Release Jan 20 2025
- Press Release Oct 24 2024
- Intimation of Board Meeting scheduled on October 24, 2024
Later from Strides Pharma Science
- Intimation on Board Meeting scheduled for May 22, 2025
- Press Release May 22 2025
- Intimation of Board Meeting scheduled on July 29, 2025
- Press Release Jul 29 2025
- Press Release Sep 08 2025
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science